• 1
    Elliott SN, McKnight W, Davies NM, MacNaughton WK & Wallace JL. Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci 1998; 62: 7791.DOI: 10.1016/s0024-3205(97)01040-0
  • 2
    Marshall JK, Rainsford KD, James C & Hunt RH. Bisphosphonate-induced gastric ulcers not associated with reduced mucosal prostaglandin E2 (PGE2): results of a randomized controlled trial(Abstract). Am J Gastroenterol 1999; 94: 26122612.
  • 3
    Lichtenberger LM, Romero JJ, Gibson GW & Blank MA. Effect of bisphosphonates on the surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci, in press.
  • 4
    Black DM, Cummings SR & Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 153541.DOI: 10.1016/s0140-6736(96)07088-2
  • 5
    Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP & Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994; 79: 15959.
  • 6
    Cohen S, Levy RM & Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 1999; 42: 230918.
  • 7
    Harris ST, Watts NB & Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. J Am Med Assoc 1999; 282: 134452.
  • 8
    Liberman UA, Weiss SR & Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 143743.
  • 9
    Reid DM, Hughes RA & Laan RFJM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15: 100613.
  • 10
    Hooper M, Ebeling P & Roberts A, et al. Risedronate prevents bone loss in early postmenopausal women(Abstract). Calcif Tissue Int 1999; 64(Suppl.1): S69S69 (P-80).
  • 11
    Reginster J-Y, Minne HW & Sorensen OH, et al. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 8391.
  • 12
    Ettinger B, Pressman A, Schein J, Chan J, Silver P & Connolly N. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm 1998; 4: 48892.
  • 13
    Spivacow FR, Zanchetta JR, Kerzberg EM, Frigeri A, Fiasche R & Roldan EJA. Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases. Curr Ther Res 1996; 57: 12330.
  • 14
    Maconi G & Porro GB. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995; 90: 188990.
  • 15
    Colina RE, Smith M, Kikendall JW & Wong RKH. A new probable increasing cause of esophageal ulceration: alendronate. Am J Gastroenterol 1997; 92: 7046.
  • 16
    De Groen PC, Lubbe DF & Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 101621.
  • 17
    Kaye PS. Gastric hemorrhage and ulceration in hiatal hernia sac associated with alendronate. Dig Dis Sci 1999; 44: 9034.
  • 18
    Simon LS, Lanza FL & Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum 1998; 41: 1591602.
  • 19
    Lanza FL, Codispoti JR & Nelson EB. An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen. Am J Gastroenterol 1998; 93: 10514.
    Direct Link:
  • 20
    Graham DY & Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther 1999; 13: 5159.DOI: 10.1046/j.1365-2036.1999.00488.x
  • 21
    Soll A. Pathogenesis of nonsteroidal anti-inflammatory drug-related upper gastrointestinal toxicity. Am J Med 1998; 105(5A): 10S16S.DOI: 10.1016/s0002-9343(98)00275-7
  • 22
    Lanza F, Rack MF, Simon T, Lombardi A, Reyes R & Suryawanshi S. Effects of alendronate on gastric and duodenal mucosa. Am J Gastroenterol 1998; 93: 7537.
    Direct Link:
  • 23
    Hetzel DJ, Dent J & Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 90312.
  • 24
    Graham DY & Malaty H. The combination of alendronate and naproxen is synergistic regarding the production of gastric ulcers. Am J Gastroenterol 1999; 94: 26092609(Abstract).
  • 25
    Lanza FL, Hunt RH, Thomson ABR, Provenza JM & Blank MA, for the Risedronate Endoscopy Study Group. A randomized endoscopy study comparing the esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119: 63163.
  • 26
    Perkins AC, Wilson CG & Frier M, et al. Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations. Int J Pharm 1999; 186: 16975.DOI: 10.1016/s0378-5173(99)00172-6
  • 27
    Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endos Clin N Am 1996; 6: 489504.
  • 28
    Lanza FL, Rack MF & Simon TJ, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999; 13: 7617.DOI: 10.1046/j.1365-2036.1999.00529.x
  • 29
    Laine L, Harper S & Simon T, et al. for the Rofecoxib Osteoarthritis Endoscopy Study Group. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 77683.
  • 30
    Laine L. Rolling review: upper gastrointestinal bleeding. Aliment Pharmacol Ther 1993; 7: 20732.
  • 31
    Laine L. Upper gastrointestinal tract hemorrhage. West J Med 1991; 155: 2749.
  • 32
    Graham DY & Malaty HM. Drug-induced gastric ulcers are caused by more than just NSAIDs: Alendronate gastric ulcers. Gastroenterology 1998; 114: A138A138(G0564) (Abstract).
  • 33
    Pounder R. Silent peptic ulceration: deadly silence or golden silence. Gastroenterology 1989; 96 (2 Part; 2(Suppl.): 62631.